Appendix: Target population data

Size: px
Start display at page:

Download "Appendix: Target population data"

Transcription

1 Appendix: Target population data

2 MabThera-Rituxan/GA101: Follicular Non-Hodgkin s Lymphoma (NHL) ,800 24,700 Incident cases 39,400 21, Drug treated indolent 1st-line 19,700 11,800 5,600 7,900 5,700 Drug treated follicular 1st-line 11,300 Drug treated follicular relapsed Sources: Cancer Incidence in Five Continents, Vol. IX, Curado. M. P et al (2007), IARC Scientific Publications No. 160, Lyon, IARC; World Population Prospects; 2008 revision; medium variant; MabThera patient flow model; & patient case market research Q Estimates only; based on Census Bureau, SEER, Mattson Jack TA data, and Q Rituxan tracking; GNE Hematology Epi Model 2

3 MabThera-Rituxan/GA101: Diffuse large B-Cell Non-Hodgkin s Lymphoma (DLBCL) ,900 40,400 19, ,100 10,700 20,900,300 10,400 Incident cases DLBCL 1st-line DLCL relapsed Drug treated Sources: Cancer Incidence in Five Continents, Vol. IX, Curado. M. P et al (2007), IARC Scientific Publications No. 160, Lyon, IARC; World Population Prospects; 2008 revision; medium variant; MabThera patient flow model; & patient case market research Q Estimates only; based on Census Bureau, SEER, Mattson Jack TA data, and Q Rituxan tracking; GNE Hematology Epi Model 3

4 MabThera-Rituxan/GA101/GDC-0199: Chronic Lymphocytic Leukemia (CLL) ,900 18, ,400 5,400 14,400 8, Incident cases CLL 1st-line CLL relapsed Drug treated Sources: Cancer Incidence in Five Continents, Vol. IX, Curado. M. P et al (2007), IARC Scientific Publications No. 160, Lyon, IARC; World Population Prospects; 2008 revision; medium variant; MabThera patient flow model; & patient case market research Q Estimates only; based on Census Bureau, SEER, Mattson Jack TA data, and Q Rituxan tracking; GNE Hematology Epi Model 4

5 Avastin: Colorectal Cancer (CRC) The potential target population for Avastin in first-line colorectal cancer is ~11800 drug treated patients (4000 /7800 ); the potential target population in second-line colorectal cancer is ~6700 chemo treated patients (25,500 /41,500 ) mcrc 1L incidence mcrc 1L drug treated 41,500 25,500 mcrc 2L chemo treated Source: Team analysis and SEER Database WHO mortality database World Population Prospects. The 2008 Revision. UN Population Division internal estimates NB: EU Avastin eligibility, no cut is made for patients who are contraindicated for Avastin all drug treated patients are assumed eligible for Avastin 5

6 Avastin: Non-Small Cell Lung Cancer (NSCLC) The potential target population for Avastin in first-line non-small cell lung cancer is ~10700 non-squamous drug treated patients (5100 /5600 ) mnsclc incidence mnsclc non-squamous mnsclc 1L non-squamous drug treated Top 5 EU mnsclc is defined as stage IIIB/IV NSCLC Sources: SEER Database: Incidence - SEER 17 Regs Research Data ( ) released April 2011; Table 1. Annual Estimates of the Resident Population by Sex and Five-Year Age Groups for the United States: April 1, 2000 to July 1, 2009 (NC-EST ). U.S. Census Bureau, Population Division. Release Date: June 2010; Table 12. Projections of the Population by Age and Sex for the United States: 2010 to 2050 (NP2008-T12). Population Division, U.S. Census Bureau. Release Date: August 14, 2008; UHC and Medicare Claims; Center for Health Statistics smoking trends data. WHO mortality database World Population Prospects. The 2008 Revision. UN Population Division Roche-Genentech Clinical, Patient Chart Audits; internal estimates 6

7 Avastin HER2-negative metastatic Breast Cancer (mbc) The potential target population for Avastin in first-line HER2-negative metastatic breast cancer is ~66,400 chemo-treated patients (2900 /37,400 ); in second-line HER2-negative metastatic breast cancer the potential target population is ~45,500 chemo treated patients (2300 /22,500 ) ,800 66,400 37,400 45,500 22, mbc HER2-negative incidence mbc HER2-negative 1L chemo treated mbc HER2-negative 2L chemo treated Sources: SEER Database, (raw incidence by Stage of breast cancer and overall survival rates for metastatic patients), Census. WHO, mortality database World Population Prospects. The 2008 Revision. UN Population Division Roche-Genentech Clinical, Patient Chart Audits Note: Includes 1L and 2L patient populations only 7

8 Avastin: Glioblastoma Multiforme (GBM) The potential target population for Avastin in first-line GBM is ~21,400 Avastin-eligible, drug treated incident patients (9,100 /12300 ). The potential target population for Avastin in relapsed GBM is ~13,200 Avastin-eligible, drug treated incident patients ( 5,500 /7,700 ) , Total diagnosed incident brain & CNS 13,700 12,300 11,500 9,100 Total diagnosed incident GBM 21,400 Avastin-eligible drug treated incident GBM (1L) 13,200 Source(s): Institut de vielle sanitaire : Assoziatione Italiana Registry Tumori: Gemeinsames Krebsregister Jahresbericht: SEER Cancer Stat Fact Sheet, Cancer of the Brain and Other Nervous System; Mattson Jack Brain Cancer Epidemiology, December 2007, Mattson Jack Cancer Treatment Architecture, December 2007, Avastin Market Planning primary market research; WHO, mortality database World Population Prospects. The 2008 Revision. UN Population Division internal estimates Note: Genentech assumes 75%-80% of incident patients are eligible for drug treatment **Avastin for relapsed GBM is not approved in EU 7,700 5,500 Avastin-eligible drug treated incident GBM (Relapse) 8

9 Avastin: Ovarian Cancer The potential target population for Avastin in front line ovarian cancer is ~3600 drug treated incident patients (17,700 /18,300 ) The potential target population for Avastin in 2 nd -line platinum sensitive ovarian cancer is ~1700 drug treated incident Avastin naïve patients (700 /1000 ) , ,500 OC incidence 17,700 Front line chemo treated nd line chemo treated platinum sensitive ** EU label is FL stage IIIb-IV (GOG-218) labels expected to reflect eligibility of ICON7 and OCEANS in 1L and 2LPS, respectively Sources: SEER Database Mattson-Jack/DaVinci, Cancer!Mpact, December Census Update WHO mortality database World Population Prospects. The 2008 Revision. UN Population Division Roche-Genentech Clinical, Patient Chart Audits, ZS Epidemiological model,

10 Avastin: Renal Cell Carcinoma (RCC) The potential target population for Avastin in first-line metastatic renal cell cancer is ~28,100 drug treated incident patients (15,100 /1300 ) , , ,400 15,100 Newly diagnosed all RCC Drug treated incident stage IV RCC Sources: SEER Database Mattson-Jack/DaVinci, Cancer!Mpact, December Census Update WHO mortality database World Population Prospects. The 2008 Revision. UN Population Division internal estimates; Market Planning Quarterly Tracking Studies 10

11 Herceptin: HER2+ early Breast Cancer (ebc) The target population for Herceptin in HER2+ early (adjuvant) breast cancer is ~7000 patients (3600 /3400 ) , , , ,500 Total BC incidence Stage I, II, III Drug treated HER2 tested HER2+ Source: A Breast Cancer Epi Model; Curado. M. P. et al (2007), Cancer Incidence in Five Continents, Vol. IX; World Population; HER2 Forecast Model. Prospects. The 2008 Revision. United Nations Population Division

12 2012 Estimated Incidence HER2+ metastatic Breast Cancer (mbc) The target and population for 1L HER2+ metastatic breast cancer is ~1800 patients (600 de novo and 1200 adjuvant relapse) The target and population for 2L-4L HER2+ metastatic breast cancer is ~2600 patients (~1400 /~1200 ) ,500 1L Patients (Top5 EU) 1L Patients () Adjuvant relapse De Novo 6,400 3,300 5,400 2, ,300 3,300 2,800 Stage IV HER2 Tested 1L HER2+ De Novo HER2+ Rx opportunities 5 EU 2L 6, L 4,700 3,200 4L 3,250 1,500 Source: A Breast Cancer Epi Model; WHO mortality database World Population Prospects. The 2008 Revision. UN Population Division internal estimates Stage IV=newly diagnosed cases of stage IV BC; HER2 Forecast Model 12

13 2012/2017 estimates for number of patients Herceptin: HER2+ 1L metastatic Gastric Cancer In 2017, the target population for Herceptin in HER2+ metastatic gastric cancer is approximately 9,300 eligible patients (4,900 /4,400 ) ,900 38,500 21,400 23,300 27,200 34,700 16,200 17,700 3,500 4,400 4,400 4, Incident advanced stage patients HER2 tested 9,300 Herceptin eligible Note: HER2 Testing and eligible assumptions differ between and 5 EU; Source: GC Forecast Model. 13

14 Xeloda: Metastatic Colorectal Cancer (mcrc) The target population for Xeloda in mcrc is ~22400 eligible drug treated incident patients (8000 /14400 ). Of the drug treated population, the target population in first-line and second-line mcrc is ~4000 and ~2600 patients, respectively patients 3 rd line st line nd line Drug treated incident CRC Drug treated mcrc Xeloda eligible mcrc Drug treated patients=all patients who begin a treatment in a new line of therapy Source: Team Analysis, SEER Database ; WHO mortality database World Population Prospects. The 2008 Revision. UN Population Division Roche-Genentech Clinical, Patient Chart Audits; internal estimates; Curado. M. P., et al (2007), Cancer Incidence in Five Continents, Vol. IX, IARC Scientific Publications No. 160, Lyon, IARC 14

15 Xeloda: Metastatic Breast Cancer (mbc) The target population for Xeloda in metastatic breast cancer in 2012 is ~19300 eligible drug treated incident patients (10000 /9300 ) patients 3 rd line+ 1 st line Drug treated BC Drug treated mbc Xeloda eligible mbc 2 nd line 3100 *Drug treated patients=all patients who begin a treatment in a new line of therapy Adjuvant HER2- patients are drug treated while metastatic HER2- patients are chemo treated. Source: Team Analysis, SEER Database WHO mortality database World Population Prospects, the 2008 Revision. UN Population Division Internal estimates; Curado. M. P., et al (2007), Cancer Incidence in Five Continents, Vol. IX, IARC Scientific Publications No. 160, Lyon, IARC 15

16 22012 estimates for number of patients Tarceva: Non-Small Cell Lung Cancer (mnsclc) EGFR mutation positive ~ 11% 5 EU EGFR mutation negative ~ 89% Incidence mnsclc* 7200 mnsclc 1st line drugtreated mnsclc 2nd line drugtreated mnsclc 3rd line +drugtreated EGFR mutation positive ~ 23% EGFR mutation negative ~ 77% *Total metastatic NSCLC newly diagnosed or newly progressed drug treated patients Sources: information, SEER Annual Cancer Review ; Census; Mattson Jack; UHC and Medicare Claims; IntrinsiQ; Synovate Tandem. WHO mortality database World Population Prospects. The 2008 Revision. UN Population Division Roche-Genentech Clinical, Patient Chart Audits; internal estimates 16

17 2012 estimates for number of treated newly diagnosed or progressed pancreatic cancer patients Tarceva: Metastatic Pancreatic Cancer The potential target population for Tarceva in first-line metastatic pancreatic cancer is ~6000 newly diagnosed and drug treated patients (2700 /2900 ) 70'000 60' '000 40'000 30'000 35'000 29'000 20'000 10'000 30'000 27'000 9'000 15'000 '0 Total advanced pancreatic patients Advanced pancreatic 1st line Advanced pancreatic 2nd line Advanced =Stage IIIB/IV in and Stage IV in EU Sources: information, SEER Annual Cancer Review ; Census; Mattson Jack; UHC and Medicare Claims; IntrinsiQ; Synovate Tandem. WHO mortality database World Population Prospects. The 2008 Revision. UN Population Division internal estimates 17

18 Zelboraf: 1st line metastatic Melanoma Cancer The target population for Zelboraf in 1L BRAF mutation positive metastatic melanoma is ~9,100 drug treated patients (4,500 /4,600 ) ,200 9, ,900 4,600 4,450 mm 1st line drug treated incidence BRAF mutation positive Sources: information from SEER Annual Cancer Review ; Census; WHO mortality database World Population Prospects. The 2008 Revision. UN Population Division Roche-Genentech Clinical, Patient Chart Audits; internal estimates 18

19 Zelboraf: Adjuvant Melanoma Cancer The target population for Zelboraf in BRAF mutation positive stage IIc and III melanoma is ~7,100 drug treated patients (2,100 /500 ) ,700 6,600 Incidence (stage IIc and III) ,100 Drug treated incidence 7, ,100 BRAF mutation positive Sources: information from SEER Annual Cancer Review ; Census; WHO mortality database World Population Prospects. The 2008 Revision. UN Population Division Roche-Genentech Clinical, Patient Chart Audits; internal estimates 19

20 (000) Erivedge (vismodegib): Advanced Basal Cell Carcinoma The target population for Erivedge in metastatic and locally advanced basal cell carcinoma is ~4000 patients (2800 / 1200 ) 2, ,600 1, K 1'500 K 40 0 BCC incidence 40 K 12 K 28 K 28K Advanced BCC incidence *Basal cell carcinoma is not tracked in most cancer registries, including SEER. Prevalence is estimated from incidence rates reported in literature and primary market research. Source: BCC Market Sizing Study, W & EU5 Market Sizing Study, Lucas RM et al: Global burden of disease from solar ultraviolet radiation. In: Prüss-Üstün et al (eds.) Environmental Burden of Disease Series No 13. Geneva: WHO 2006; WHO mortality database World Population Prospects. The 2008 Revision. UN Population Division Roche-Genentech Clinical, Patient Chart Audits; internal estimates 20

21 2012 estimates for number of treated newly diagnosed or progressed NSCLC patients MetMAb: Non-Small Cell Lung Cancer (mnsclc) 350' ' ' ' ' ' '000 93'000 47,500 24,500 50'000 '0 134'000 Incidence mnsclc* 72'000 mnsclc 1st line drug treated 51'000 43'100 mnsclc 2nd line drug treated 25'500 21'000 10'500 22'000 28'300 14'150 mnsclc 2nd line Met Dx+ mnsclc 3rd line+ drug treated mnsclc 3rd line Met Dx+ *Total metastatic NSCLC newly diagnosed or newly progressed patients Sources: information, SEER Annual Cancer Review ; Census; Mattson Jack; UHC and Medicare Claims; IntrinsiQ; Synovate Tandem. WHO mortality database World Population Prospects. The 2008 Revision. UN Population Division Roche-Genentech Clinical, Patient Chart Audits; internal estimates 21

22 Lucentis: Age-related Macular Degeneration (AMD) Of the ~560k patients with wet AMD (wamd), our potential U.S. target patient population is ~280k patients in New patients Existing patients wamd population Presenting/ diagnosed population Treated population Source: Klein R et al. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007 Feb;114(2): ; Klein R et al. Prevalence of age-related macular degeneration in the population. Arch Ophthalmol 2011 Jan;129(1):75-80; Census; Roche-Genentech Clinical, Patient Chart Audits, 2007 wamd Buying Process; internal estimates 22

23 Lucentis: Diabetic Macular Edema (DME) Of the ~700k patients with DME, we believe our Lucentis U.S. target population is ~170k patients in New patients Existing patients DME population Vision loss Presenting/ diagnosed Treated population Sources: Bressler NM, Varma R, Doan Q, et al. Prevalence of Visual Impairment from Diabetic Macular Edema and Relationship to Eye Care from the National Health and Nutrition Examination Survey (NHANES) extrapolated to 2012; The Retina Society 45th Annual Scientific Meetings, Washington, DC; October 4 7, 2012 (accepted for presentation); Eye Diseases Prevalence Research Group (EDPRG) paper April 2004; 2008 DME Buying Process; Roche-Genentech Clinical, Patient Chart Audits; internal estimates 23

24 Lucentis: Retinal Vein Occlusion (RVO) Of the ~290k patients with CRVO, our potential U.S. target patient population is 40k patients in estimates for CRVO target population ,400 Of the ~870k patients with BRVO, we believe our potential U.S. target patient population is 50k patients in estimates for BRVO target population , CRVO population ,200 21, ,300 18,100 Rate of vision loss Presentation/ Treatment rate Diagnosis rate ,600 BRVO population ,200 44,200 52,200 32,700 27,800 20,600 Rate of Presentation/ Treatment rate vision loss Diagnosis rate Existing patients New patients BRVO=Branch Retinal Vein Occlusion; CRVO=Central Retinal Vein Occlusion. Source: Klein R et al. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 2008 Apr;126(4): ; Klein R et al. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98: ; discussion ; The Branch Vein Occlusion Study Group. (1984). Am J Ophthalmol, 98(3), ; 2008 RVO Buying Process Research; Roche-Genentech Clinical, Patient Chart Audits; internal estimates 24

25 Rituxan and Actemra: TNF-IR Rheumatoid Arthritis Our global target population for MabThera/Rituxan and Actemra in rheumatoid arthritis is ~900k bio eligible patients. : Target population for MabThera is Bio-IR (2L+: 85k), for ACTEMRA it is all biologics (~190k) : Target Population for Rituxan and Actemra* is BIO IR (2L+: ~330k) (in millions) 2012 estimates for target population BIO-IR (2L+) DMARD-IR (1L) Diagnosed RA patients Mod-to-Sev RA patients Mod-to-Sev treated RA patients Biologic treated , *1 st line indication pending FDA approval in October 2012 Sources: 2011 Equinox EPI Research and Modeling, 2011 survey of published RA epidemiology literature including 2010 based study, 2011 literature review of most recent sources ( ), primary market research (Rheum ATU, GfK rheum report, Synovate Chart Audit, Adelphi, Decision Resources, etc.), Claims data analysis (2011); Updated for BP2012 5EU Sources: RA Bio-Population alignment (based on BlackSwan assessment); RA Tracker Adelphi & Genactis 2011 and

26 Actemra: Systemic Juvenile Idiopathic Arthritis (sjia) : The target sjia patient population is estimated to be ~5,700 who are eligible for treatment with Actemra the first and only FDA approved therapy EU5: The bio eligible sjia sjia target population is estimated to be ~1,500 patients potential target population 5,950 EU5 ~7,200 1,480 patients per line 1L ~2.6K 2L ~2.1K 3L ~1.1K ,700 Prevalent population Diagnosed and treated Sources: : Q4 2011sJIA Market Research, 2010 sjia ad-board, CDC NHANES, Global Epi Group, EU5: GHEP Epidemiology 26

27 Rituxan: ANCA-Associated Vasculitis 2012 potential target population Label from FDA indicated for GPA and MPA only Actively treated patients may enter remission Patients in remission may re-enter actively treated upon disease flare-up 41K Diagnosed Diagnosed AAV patients in 2012 Eligible for Rituxan 19K WG 15K MPA 7K CS Patients by disease type 18K Active Tx WG/MPA 3K Active Tx CS 20K In remission Actively treated vs. In remission at any given time GPA=Granulomatosis with polyangiitis, MPA=Microscopic polyangiitis, CS=Churg-Strauss syndrome, ANCA=antineutrophil cytoplasmic antibodies Source: Triangulation and analysis using multiple published studies and primary market research, including: Watts, et al. Epidemiology of ANCA-associated Vasculitis. Rheumatic Disease Clinics of North America. 2010, August; 36 (3): ; Koldingsnes, et al. Epidemiology of ANCA associated vasculitis. Norsk Epidemiologi 2008; 18 (1): 37-48; Rituxan AAV Forecast Research, January 2011; Rituxan GPA/MPA Opportunity Assessment, February

28 2014 estimates for number of patients Xolair: Chronic Idiopathic Urticaria (CIU) potential target population 2014 U.S. Xolair eligible patients seen by Target MDs = ~78,500 patients , , , Diagnosed CU Idiopathic Age 12+ RX treated Non-responsive to RX therapy 78,549 Seen by biologic prescriber Sources include: CIU Market Research with physicians (Q2 2012), Genentech Burden of Illness Report (2010), Greaves (2007), Tong (1997), Kaplan (2002), Najib (2009), Xolair team input 28

29 Xolair: Allergic asthma 2012 U.S. Xolair eligible patients seen by Target MDs = ~38200 patients 2012 potential target population , Treated 54% Moderate/Severe 40% Uncontrolled 55% IgE Mediated 2,217 60% 67% 43% 1,330,891,382 Diagnosed Asthmatics (12+) Treated Asthmatics Moderate and Severe Uncontrolled Allergic Within dosing table Seen by ALs, PUDs, and select PCPs Sources include: Department of Health & Human Services, Vital & Health Statistics, Dec 2006, Trends in Asthma Morbidity & Mortality, August 2007, REACT, AAAAI, TENOR, IMS Dx. Updated prevalence based on CDC Data Jan

30 Lebrikizumab: Severe uncontrolled adult asthma 2500 Forecasted estimates for target population ,152 Treated asthmatics 4,428 ~200* 1,204 1,442,793 Treated w high dose ICS Uncontrolled * Lebrikizumab eligible patients (periostin high) are a subset of this population Sources: Department of Health & Human Services, Vital & Health Statistics, Dec 2006, Trends in Asthma Morbidity & Mortality, August 2007, REACT, AAAAI, TENOR, IMS Dx. Updated prevalence based on CDC Data Jan 2011, Phase II MLLY trial, January 2011 Market Research 30

31 Patients (000s) Schizophrenia The target population of diagnosed Schizophrenic patients with residual symptoms is ~2.4M patients (1,323M /180M EU) potential target population 400 Target patient population 300 1,986 1,847 1,588 ~2.4m ,375 2,197 1,889 1,323 Schizophrenic prevalence Schizophrenics diagnosed Treated schizophrenics Schizophrenics with Neg and/or Pos symptoms Sources: Decision Resources, Data Monitor, Roche Epidemiology Group Sources: McGrath et. al., 2008 (Prevalence); Adelphi time to mortality data (Diagnosed); WK PLD Analysis 2010, Adelphi Database 2010, Weiden & Olfson et al., 1990, ECA, 1991, Internal Patient Flow Model (Treatment Rate); Internal Schizophrenia Chart Audit (residual symptoms) 31

32 2nd generation anti-cd20: Relapsing Multiple Sclerosis (RMS) Potential target population for 2nd generation anti-cd20 for Relapsing Multiple Sclerosis (RMS) is ~47500 patients (250,300 /22300 EU) ~ ,300 Diagnosed prevalence Treated population Source: Genentech/Roche internal assumptions 32

33 2nd generation anti-cd20: Primary Progressive Multiple Sclerosis (PPMS) Potential target population for 2nd generation anti-cd20 for Primary Progressive Multiple Sclerosis (PPMS) is ~ 38,400 patients (18,400 /2000 EU5) ,200 Prevalence ~38, ,400 Treated population Source: Genentech/Roche internal assumptions 33

34 No. of Patients in 2012 (000s) Alzheimer s Disease target population The target population of diagnosed, treated Mild, Moderate and Severe Alzheimer s patients is ~1, potential target population 300 2,500,352 Alzheimer's Severe 200 1,500 2, , m Moderate Mild 100,500 Prevalent population 1,356 Mild & moderate population,708,609 Dx'd population,292,537,330 Tx'd population Source: Plassman (2007), IMS Claims Data, Internal Roche/GNE Data 34

35 No. of Patients in 2012 (000s) Alzheimer s Disease 5EU target population The target population of diagnosed, treated Mild, Moderate and Severe Alzheimer s patients is ~1, potential EU5 target population 300 2,500,365 Alzheimer's Severe Moderate 1,500 2,806, m Mild 100,500 Prevalent population 1,403 Mild & moderate population,733,630 Dx'd population,302,555,341 Tx'd population Source: Plassman (2007), IMS Claims Data, Internal Roche/GNE Data 35

36 Global prevalence of chronic HBsAg infection HBsAg Prevalence 8% - High 2-7% - Intermediate <2% - Low WHO estimate ~350 million global chronic HBV infections Source: WHO Hepatitis B Department of Communicable Diseases Surveillance and Response Report, WHO/CDS/CSR/LYO/2002.2: Hepatitis B. 36

37 Chronic HBsAg patients (N) Chronic HBsAg prevalence in Developed Markets (France, Germany, Italy and A) 2012 potential target population,3.0,2.5, m 2.0m,1.5, m 0.8m Chronic anti-hbsag Diagnosed chronic anti-hbsag 37

38 Chronic HBsAg patients (N) Chronic HBsAg prevalence in Emerging Markets (China [urban], Brazil, Turkey) 2012 potential target population,100.0, m,60.0,40.0, m 51m 24m Chronic anti-hbsag Diagnosed chronic anti-hbsag

39 Number of patients with ACS & T2D (excluding CHF stage II-IV, 000 s) Aleglitazar Objective: Reduction of CV mortality, non-fatal MI, stroke, following a recent ACS in adults with concomitant T2D Top 5EU Source: Internal Roche and Genentech forecasts using National Center for Health Statistics NHANES () and country-specific data (ex-) 39

Roche Committed to innovation and profitable growth. Dr. Karl Mahler Head of Investor Relations. London, July 2011

Roche Committed to innovation and profitable growth. Dr. Karl Mahler Head of Investor Relations. London, July 2011 Roche Committed to innovation and profitable growth Dr. Karl Mahler Head of Investor Relations London, July 2011 2 This presentation contains certain forward-looking statements. These forward-looking statements

More information

+4.7 +4.3 +3.9 +6.2 +4.5. Net debt (6,708) (10,599) 37 38. Capitalisation 39,884 41,340 4 +2 Debt 18,643 24,590 24 22 Equity 21,241 16,750 +27 +37

+4.7 +4.3 +3.9 +6.2 +4.5. Net debt (6,708) (10,599) 37 38. Capitalisation 39,884 41,340 4 +2 Debt 18,643 24,590 24 22 Equity 21,241 16,750 +27 +37 Finance Report Finance in brief Key results Sales CER growth % Core operating profit margin, % of sales Pharmaceuticals 2013 +6.7 2012 +4.7 44.4 44.0 Diagnostics 2013 2012 +4.3 +3.9 20.8 21.3 Group 2013

More information

Roche reports solid sales growth in the first quarter of 2016

Roche reports solid sales growth in the first quarter of 2016 Media Release Basel, 19 April 2016 Roche reports solid sales growth in the first quarter of 2016 Group sales up 4% 1 at constant exchange rates, 5% in Swiss francs Pharmaceuticals Division sales increase

More information

Core results Research and development 8,913 8,700 +2 +4 18.8 18.6 Core operating profit 17,636 17,904 1 +3 37.2 38.3 Core EPS (CHF) 14.29 14.

Core results Research and development 8,913 8,700 +2 +4 18.8 18.6 Core operating profit 17,636 17,904 1 +3 37.2 38.3 Core EPS (CHF) 14.29 14. Finance Report 2014 Finance in brief Key results Sales CER growth % Core operating profit margin, % of sales Pharmaceuticals 2014 +4.5 2013 +6.7 43.6 44.4 Diagnostics 2014 2013 +6.4 +4.3 19.5 20.8 Group

More information

FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema

FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema Media Release Basel, 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema First major treatment advance in more than 25 years for sight-threatening condition

More information

Risks for the Swiss Pharmaceutical Market in 2013

Risks for the Swiss Pharmaceutical Market in 2013 Media Release Úten morgen her speck! Basel, 25 July 2013 Roche posts strong first-half results Group sales 5% 1 higher at 23.3 billion Swiss francs Core EPS 12% higher at 7.58 Swiss francs; net income

More information

Roche A sustainable business model based on innovation and productivity gains

Roche A sustainable business model based on innovation and productivity gains Roche A sustainable business model based on innovation and productivity gains William M. Burns, CEO Roche Pharmaceuticals Vontobel Summer Conference 2009, Interlaken 1 This presentation contains certain

More information

David Loew, LCL MabThera

David Loew, LCL MabThera MabThera The star continues to rise David Loew, LCL MabThera MabThera the star continues to raise Group sales (CHF bn) 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 2001 2002 2003 2004 2005 Outstanding clinical

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Roche reports strong sales growth in the first quarter of 2015. medicines, Avastin, MabThera/Rituxan) and immunology (Actemra/RoActemra, Xolair)

Roche reports strong sales growth in the first quarter of 2015. medicines, Avastin, MabThera/Rituxan) and immunology (Actemra/RoActemra, Xolair) Media Release Basel, 22 April 2015 Roche reports strong sales growth in the first quarter of 2015 Group sales up 5% at constant exchange rates (CER) 1, 3% in Swiss francs Pharmaceuticals Division sales

More information

+0.1 +3.9 +5.9 +4.5 +1.4

+0.1 +3.9 +5.9 +4.5 +1.4 Finance Report Finance in brief Key results Sales CER growth % Core operating profit margin, % of sales Pharmaceuticals 2012 +4.7 2011 +0.1 44.0 40.9 Diagnostics 2012 2011 +3.9 +5.9 21.3 22.4 Group 2012

More information

Key figures 2015 CHF millions % change

Key figures 2015 CHF millions % change Media Release Basel, 28 January 2016 Roche reports strong results in 2015 Group sales increased by 5% 1 at constant exchange rates, 1% in Swiss francs Pharmaceuticals Division sales up 5%, driven by oncology

More information

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets

More information

F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland Half-Year Report 2013 All trademarks are legally protected. www.roche.com 2013

F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland Half-Year Report 2013 All trademarks are legally protected. www.roche.com 2013 Half-Year Report 2013 Finance in brief Key interim results Sales CER growth % Core operating profit margin, % of sales Pharmaceuticals 2013 +5.7 2012 +3.8 46.9 45.3 Diagnostics 2013 2012 +2.6 +5.1 21.1

More information

Lung Cancer: More than meets the eye

Lung Cancer: More than meets the eye Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research

More information

REFERENCE CODE GDHCER083-15 PUBLICAT ION DATE JULY 2015 MULTIPLE MYELOMA EPIDEMIOLOGY FORECAST TO 2023

REFERENCE CODE GDHCER083-15 PUBLICAT ION DATE JULY 2015 MULTIPLE MYELOMA EPIDEMIOLOGY FORECAST TO 2023 REFERENCE CODE GDHCER083-15 PUBLICAT ION DATE JULY 2015 MULTIPLE MYELOMA Executive Summary Multiple myeloma (MM) (International Statistical Classification of Diseases and Related Health Problems, 10th

More information

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

Autoimmune Diseases More common than you think Randall Stevens, MD

Autoimmune Diseases More common than you think Randall Stevens, MD Autoimmune Diseases More common than you think Randall Stevens, MD picture placeholder Autoimmune Diseases More than 60 different disorders Autoimmune disorders (AID) diseases caused by the immune system

More information

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable

More information

F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland. All trademarks are legally protected. www.roche.com. Finance Report 2015. Roche

F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland. All trademarks are legally protected. www.roche.com. Finance Report 2015. Roche F. Hoffmann-La Roche Ltd 4070 Basel, Switzerland 2016 All trademarks are legally protected. www.roche.com Roche Finance Report 2015 0 000 000 E Finance Report 2015 Finance in brief Key results Sales CER

More information

Roche on track for full-year targets good sales growth in first quarter

Roche on track for full-year targets good sales growth in first quarter Investor Update Basel, 12 April 2012 Roche on track for full-year targets good sales growth in first quarter Group sales rise 2% at CER 1 (-1% in Swiss francs; +1% in US dollars) to 11.0 billion Swiss

More information

Co-pay assistance organizations offering assistance

Co-pay assistance organizations offering assistance Acromegaly Acute Exacerbations of Multiple Sclerosis Acute Porphyrias Advanced Idiopathic Parkinson' s Disease Age-Related Macular Degeneration www.theassistancefund.org Alcohol Dependence Alpha-1 Antitrypsin

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Roche delivers strong performance in the first half of 2015

Roche delivers strong performance in the first half of 2015 Media Release Basel, 23 July 2015 Roche delivers strong performance in the first half of 2015 Group sales up 6% at constant exchange rates 1, 3% in Swiss francs Pharmaceuticals Division sales up 5%, driven

More information

Roche: Ensuring sustained success in a more challenging environment

Roche: Ensuring sustained success in a more challenging environment Roche: Ensuring sustained success in a more challenging environment JP Morgan - January 2011 Dr. Erich Hunziker, Deputy Head of the Corporate Executive Committee and CFO This presentation contains certain

More information

Core therapeutic areas

Core therapeutic areas Core therapeutic areas Platforms for growth Luke Miels, Executive Vice President, Global Portfolio & Product Strategy and Corporate Affairs Current business is led by core therapeutic areas Sales 9M 2014

More information

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and

More information

Roche delivers continued growth in the first half of 2016

Roche delivers continued growth in the first half of 2016 Media Release Basel, 21 July 2016 Roche delivers continued growth in the first half of 2016 Group sales increased by 5% 1 at constant exchange rates, 6% in Swiss francs Pharmaceuticals Division sales up

More information

Group performance at a glance

Group performance at a glance 09 Roche in Brief Excellence in Science Our Business Innovation is our answer to medical challenges. Our daily work is saving patients lives and helping millions of people around the world through excellence

More information

2015 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE. Wednesday, February 25, 2015

2015 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE. Wednesday, February 25, 2015 2015 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE Wednesday, February 25, 2015 FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements, including PDL s expectations with respect

More information

REFERENCE CODE GDHCER032-14 PUBLICAT ION DATE AUGUST 2014 RENAL CELL CARCINOMA - EPIDEMIOLOGY FORECAST TO 2023

REFERENCE CODE GDHCER032-14 PUBLICAT ION DATE AUGUST 2014 RENAL CELL CARCINOMA - EPIDEMIOLOGY FORECAST TO 2023 REFERENCE CODE GDHCER032-14 PUBLICAT ION DATE AUGUST 2014 RENAL CELL CARCINOMA - Executive Summary Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted

More information

31/10/2013. Dr Martin Eatock Consultant Medical Oncologist Chair NICaN D+T Committee. Year

31/10/2013. Dr Martin Eatock Consultant Medical Oncologist Chair NICaN D+T Committee. Year 20 Oncologists & Hematologists surveyed across Northern Ireland HSC trusts 18 Consultants, 2 SpRs 10 Oncologists, 10 Hematologists 4 Cancer service centers All with some/significant involvement in applying

More information

The Evaluation of Cancer Control Interventions in Lung Cancer Using a Canadian Cancer Risk Management Model

The Evaluation of Cancer Control Interventions in Lung Cancer Using a Canadian Cancer Risk Management Model The Evaluation of Cancer Control Interventions in Lung Cancer Using a Canadian Cancer Risk Management Model WK Evans, M Wolfson, WM Flanagan, J Shin, FF Liu JR Goffin, K Asakawa, N Mittmann, L Fairclough

More information

Three months ended 31 March

Three months ended 31 March Media Release Basel, 15 April 2010 Excellent growth in first quarter of 2010 Group sales up 9% in local currencies to 12.2 billion Swiss francs in first three months (+6% in Swiss francs, +15% in US dollars).

More information

REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for HER2-Positive Breast Cancer in China Market

More information

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014 ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the

More information

Pharmaceuticals Division sales up 4%, driven by oncology (HER2-positive breast cancer medicines,

Pharmaceuticals Division sales up 4%, driven by oncology (HER2-positive breast cancer medicines, Media Release Basel, 28 January 2015 Roche delivers solid results in 2014 Group sales up 5% at constant exchange rates 1, 1% in Swiss francs Pharmaceuticals Division sales up 4%, driven by oncology (HER2-positive

More information

Investor science conference call American Society of Hematology. 9 December 2013, New Orleans, USA

Investor science conference call American Society of Hematology. 9 December 2013, New Orleans, USA Investor science conference call American Society of Hematology 9 December 2013, New Orleans, USA Forward-looking statements This presentation contains certain forward-looking statements. These forward-looking

More information

CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early

CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early April 21, 2015 CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated

More information

Roche: Defining priorities for a high tech healthcare company

Roche: Defining priorities for a high tech healthcare company Roche: Defining priorities for a high tech healthcare company Erich Hunziker, Deputy Head of the Corporate Executive Committee and CFO January 2008 1 This presentation contains certain forward-looking

More information

Avastin (Bevacizumab) Intravitreal Injection

Avastin (Bevacizumab) Intravitreal Injection Avastin (Bevacizumab) Intravitreal Injection This handout describes how Avastin may be used to treat wet age related macular degeneration (AMD) or macular edema due to retinal vascular disease such as

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:

In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes: EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human

More information

POLICY A. INDICATIONS

POLICY A. INDICATIONS Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

Big Data and Oncology Care Quality Improvement in the United States

Big Data and Oncology Care Quality Improvement in the United States Big Data and Oncology Care Quality Improvement in the United States Peter P. Yu, MD, FACP, FASCO President, American Society of Clinical Oncology Director of Cancer Research, Palo Alto Medical Foundation

More information

Peter Kellogg, CFO. Goldman Sachs Laguna Niguel,, CA June 14, 2006. Fair Disclosure: Under Reg

Peter Kellogg, CFO. Goldman Sachs Laguna Niguel,, CA June 14, 2006. Fair Disclosure: Under Reg Peter Kellogg, CFO Goldman Sachs Laguna Niguel,, CA Fair Disclosure: Under Reg FD, the SEC has set out a series of regulations regarding selective disclosure of material non-public information. In an effort

More information

Number. Source: Vital Records, M CDPH

Number. Source: Vital Records, M CDPH Epidemiology of Cancer in Department of Public Health Revised April 212 Introduction The general public is very concerned about cancer in the community. Many residents believe that cancer rates are high

More information

Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.

Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate. EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human

More information

Costs Associated with Neutropenia in Elderly Patients Treated First-Line for Advanced Non-Small Cell Lung Cancer

Costs Associated with Neutropenia in Elderly Patients Treated First-Line for Advanced Non-Small Cell Lung Cancer Costs Associated with Neutropenia in Elderly Patients Treated First-Line for Advanced Non-Small Cell Lung Cancer Michael Stokes United BioSource Corporation ISPOR 13 th Annual International Meeting Toronto,

More information

Monoclonal antibody (mab) products are currently a fast

Monoclonal antibody (mab) products are currently a fast Antibody Monoclonal Therapeutics Janice M. Reichert, Ph.D. Monoclonal antibody (mab) products are currently a fast growing category of drugs. Like antibodies produced naturally by the human immune system,

More information

Cancer. 9p21.3 deletion. t(12;21) t(15;17)

Cancer. 9p21.3 deletion. t(12;21) t(15;17) CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)

More information

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15 Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Renal Cell Carcinoma (Event Driven)

Renal Cell Carcinoma (Event Driven) Brochure More information from http://www.researchandmarkets.com/reports/2365661/ Renal Cell Carcinoma (Event Driven) Description: The Renal Cell Carcinoma market is highly lucrative. We anticipate that

More information

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div. Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under

More information

Diagnostics: Growth through innovation and Personalised Healthcare. Daniel O Day, COO Roche Diagnostics

Diagnostics: Growth through innovation and Personalised Healthcare. Daniel O Day, COO Roche Diagnostics Diagnostics: Growth through innovation and Personalised Healthcare Daniel O Day, COO Roche Diagnostics Roche Diagnostics portfolio overview Industry leading businesses covering the entire IVD spectrum

More information

Ovarian Cancer. in Georgia, 1999-2003. Georgia Department of Human Resources Division of Public Health

Ovarian Cancer. in Georgia, 1999-2003. Georgia Department of Human Resources Division of Public Health Ovarian Cancer in Georgia, 1999-23 Georgia Department of Human Resources Division of Public Health Acknowledgments Georgia Department of Human Resources......B. J. Walker, Commissioner Division of Public

More information

Skin Cancer: The Facts. Slide content provided by Loraine Marrett, Senior Epidemiologist, Division of Preventive Oncology, Cancer Care Ontario.

Skin Cancer: The Facts. Slide content provided by Loraine Marrett, Senior Epidemiologist, Division of Preventive Oncology, Cancer Care Ontario. Skin Cancer: The Facts Slide content provided by Loraine Marrett, Senior Epidemiologist, Division of Preventive Oncology, Cancer Care Ontario. Types of skin Cancer Basal cell carcinoma (BCC) most common

More information

Fulfilling the Promise

Fulfilling the Promise Fulfilling the Promise Advancing the Fight Against Cancer: America s Medical Schools and Teaching Hospitals For more than a century, the nation s medical schools and teaching hospitals have worked to understand,

More information

IR Conference Call on EYLEA (aflibercept) Injection in Diabetic Macular Edema. September 28, 2013

IR Conference Call on EYLEA (aflibercept) Injection in Diabetic Macular Edema. September 28, 2013 IR Conference Call on EYLEA (aflibercept) Injection in Diabetic Macular Edema September 28, 2013 Safe Harbor Statement This presentation includes forward-looking statements that involve risks and uncertainties

More information

Biogen Idec Contacts: Media: Amy Brockelman (617) 914-6524 Investor: Eric Hoffman (617) 679-2812

Biogen Idec Contacts: Media: Amy Brockelman (617) 914-6524 Investor: Eric Hoffman (617) 679-2812 NEWS RELEASE Media: Nikki Levy (650) 225-1729 Investor: Susan Morris (650) 225-6523 Biogen Idec Contacts: Media: Amy Brockelman (617) 914-6524 Investor: Eric Hoffman (617) 679-2812 GENENTECH AND BIOGEN

More information

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007 Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.

More information

Current Management of Retinal Vein Occlusion Robert A. Mittra, MD VRS Course 2015

Current Management of Retinal Vein Occlusion Robert A. Mittra, MD VRS Course 2015 Central Retinal Vein Occlusion Hemi-Central Vein Occlusion Current Management of Retinal Vein Occlusion Robert A. Mittra, MD VRS Course 2015 Branch Retinal Vein Occlusion Ischemic vs. non-ischemic BRVO

More information

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

Breast Cancer Drug Discoveries: What the Future Holds

Breast Cancer Drug Discoveries: What the Future Holds Brochure More information from http://www.researchandmarkets.com/reports/679630/ Breast Cancer Drug Discoveries: What the Future Holds Description: In 2010, almost 50% of breast cancer sales were due to

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Gastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/

Gastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Gastric Cancer Description: Gastric cancer (GC) is one of the most common malignancies in terms of incidence and the second

More information

49th ASCO Annual Meeting, Chicago. Roche Analyst Event. Sunday, June 2, 2013

49th ASCO Annual Meeting, Chicago. Roche Analyst Event. Sunday, June 2, 2013 49th ASCO Annual Meeting, Chicago Roche Analyst Event Sunday, June 2, 2013 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such

More information

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,

More information

Anti-HCV therapy in HCV-related NHL

Anti-HCV therapy in HCV-related NHL Gabriele Pozzato M.D. University of Trieste Anti-HCV therapy in HCV-related NHL Questions about HCV+ in NHL Is the NHL related with HCV infection? Which is the best therapeutic strategy? Is the antiviral

More information

Page 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015

Page 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015 Moda Health Plan, Inc. Medical Necessity Criteria Subject: Actemra (tocilizumab) Page 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015

More information

Selected Health Status Indicators DALLAS COUNTY. Jointly produced to assist those seeking to improve health care in rural Alabama

Selected Health Status Indicators DALLAS COUNTY. Jointly produced to assist those seeking to improve health care in rural Alabama Selected Health Status Indicators DALLAS COUNTY Jointly produced to assist those seeking to improve health care in rural Alabama By The Office of Primary Care and Rural Health, Alabama Department of Public

More information

CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy

CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara,

More information

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

Come è cambiata la storia naturale della malattia

Come è cambiata la storia naturale della malattia Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal

More information

Chapter I Overview Chapter Contents

Chapter I Overview Chapter Contents Chapter I Overview Chapter Contents Table Number Contents I-1 Estimated New Cancer Cases and Deaths for 2005 I-2 53-Year Trends in US Cancer Death Rates I-3 Summary of Changes in Cancer Incidence and Mortality

More information

The Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion

The Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion November 2013 Edition Vol. 7, Issue 10 The Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion By Gordon Gochenauer, Director, Oncology Commercial Strategies,

More information

targeted therapy a guide for the patient

targeted therapy a guide for the patient targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting

More information

Medical Insurance Long Term (chronic) Conditions Explained

Medical Insurance Long Term (chronic) Conditions Explained Medical Insurance Long Term (chronic) Conditions Explained October 2013 FS 28452 wpa.org.uk EMS 505226 IS 553152 Introduction This leaflet explains how we manage claims for our policyholders whose medical

More information

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Update in Hematology Oncology Targeted Therapies. Mark Holguin Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning

More information

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions

More information

Cancer in Ireland 2013: Annual report of the National Cancer Registry

Cancer in Ireland 2013: Annual report of the National Cancer Registry Cancer in 2013: Annual report of the National Cancer Registry ABBREVIATIONS Acronyms 95% CI 95% confidence interval APC Annual percentage change ASR Age standardised rate (European standard population)

More information

Roche. Q1 2014 sales. Basel, 15 April 2014

Roche. Q1 2014 sales. Basel, 15 April 2014 1 Roche Q1 2014 sales Basel, 15 April 2014 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,

More information

Trials in Elderly Melanoma Patients (with a focus on immunotherapy)

Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP

More information

Age- Related Macular Degeneration

Age- Related Macular Degeneration Age- Related Macular Degeneration Age-Related Macular Degeneration (AMD) is the leading cause of blindness in the United States. It is caused by damage to a localized area of the central retina called

More information

Company Presentation June 2011 Biotest AG 0

Company Presentation June 2011 Biotest AG 0 Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and

More information

New work programme for NICE announced

New work programme for NICE announced Page 1 of 5 New work programme for NICE announced New treatments for prostate cancer, drugs misuse, osteoporosis and heart failure are being referred to the National Institute for Clinical Excellence (NICE),

More information

MEDICARE RISK ADJUSTMENT A PROSPECTIVE APPROACH TO RISK ADJUSTMENT AND ACCURATE DOCUMENTATION AND CODING

MEDICARE RISK ADJUSTMENT A PROSPECTIVE APPROACH TO RISK ADJUSTMENT AND ACCURATE DOCUMENTATION AND CODING MEDICARE RISK ADJUSTMENT A PROSPECTIVE APPROACH TO RISK ADJUSTMENT AND ACCURATE DOCUMENTATION AND CODING WHAT IS RISK ADJUSTMENT? Risk Adjustment ensures that accurate payments are made to Medicare Advantage

More information

Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Brochure More information from http://www.researchandmarkets.com/reports/3128342/ Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Description: Methotrexate (Rheumatoid Arthritis)

More information

Which eye conditions can avastin injections be used for?

Which eye conditions can avastin injections be used for? What is avastin? Avastin is a drug that is licensed for the treatment of a certain type of colorectal cancer but can also be used to treat certain eye conditions by being injected into the eye. Although

More information

Immune Modulating Drugs Prior Authorization Request Form

Immune Modulating Drugs Prior Authorization Request Form Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

More information

REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC96PIDR PUBLICATION DATE APRIL 2015 PROSTATE CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Prostate Cancer: Key Metrics in the 9MM, 2013 2023 2013 Epidemiology

More information

Roche Finance Report Roche

Roche Finance Report Roche 2010 Roche Finance Report Table of contents Roche Group 2 Finance in brief 2 Finance 2010 in brief 3 Financial Review 4 Roche Group Consolidated Financial Statements 34 Notes to the Roche Group Consolidated

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure

More information

Ovarian Cancer (Event Driven)

Ovarian Cancer (Event Driven) Brochure More information from http://www.researchandmarkets.com/reports/2367241/ Ovarian Cancer (Event Driven) Description: Owing to the lack of screening programs across the markets under study, ovarian

More information

Chapter 7: Lung Cancer

Chapter 7: Lung Cancer Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin

More information

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center

More information

Kempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011

Kempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011 Kempen & Co 4 th Healthcare/Life Sciences Conference Brussels March 29, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included

More information

Measures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University

Measures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

We Innovate Healthcare

We Innovate Healthcare Part 2 Roche Annual Report 2006 Finance Report We Innovate Healthcare Innovation spanning the entire healthcare spectrum As a pharmaceuticals and a diagnostics company, Roche brings pioneering products

More information